Benzinga | Oct 23, 2020 11:48AM EDT

Oppenheimer Initiates Coverage On CASI Pharmaceuticals with Outperform Rating, Announces Price Target of $5

Oppenheimer analyst Leland Gershell initiates coverage on CASI Pharmaceuticals (NASDAQ:CASI) with a Outperform rating and announces Price Target of $5.